Business Wire

Philip Morris International Applauds U.K. Government’s Approach to Achieve its Smoke-Free Ambition

Share

Philip Morris International Inc. (PMI) (NYSE: PM) announced its support of the U.K. government’s plan to simplify the pathway to license electronic cigarettes and other inhaled nicotine-containing products (NCPs) as medicines in England. The U.K. already has one of Europe’s lowest smoking rates, supported by a high rate of smokers who have switched to better alternatives. This proposal makes the U.K. the first country in the world to encourage the medical licensing of e-cigarettes via prescription as a route to further lower smoking rates, particularly among low-income smokers.

Sajid Javid, Health and Social Care Secretary, announced that this will “tackle the stark disparities in smoking rates across the country, helping people stop smoking wherever they live and whatever their background.” The announcement notes that “e-cigarettes contain nicotine and are not risk-free, but expert reviews from the U.K. and U.S. have been clear that the regulated e-cigarettes are less harmful than smoking.” Importantly, this measure is not taken in isolation but complements existing policies to encourage switching from cigarettes to e-cigarettes as a way to accelerate the transition to a smoke-free U.K. The U.K. government recognizes the role of e-cigarettes supporting those trying to quit, with 27.2% of smokers using them compared with 18.2% using nicotine replacement therapy products1.

Gregoire Verdeaux, Senior Vice President, External Affairs at Philip Morris International commented:

“The U.K. is a global leader in medicine, science and public health. Expert scientific reviews in the U.K. and U.S. are clear that smoke-free alternatives—such as e-cigarettes—offer adults who would otherwise continue to smoke cigarettes a better alternative. We welcome the U.K. government’s continued recognition that regulated e-cigarettes and other inhaled nicotine-containing products, while not risk-free, are less harmful than smoking and can significantly benefit public health.

“The U.K. government’s progressive approach to tobacco harm reduction has already contributed to a high number of smokers using better alternatives like e-cigarettes to move away from cigarettes2, and also one of Europe’s lowest smoking rates3. This newly simplified, regulated prescription pathway brings an additional opportunity to help those in the poorer areas of England—where smoking prevalence is disproportionately high—abandon cigarettes.

“The U.K. government also recognizes the importance of differentiated taxation of non-prescription smoke-free products, incentivizing adult smokers who don’t quit tobacco and nicotine altogether to switch to less harmful alternatives by taxing the most harmful products—cigarettes—the most, and less harmful non-combustible alternatives, the least.

“Income inequality affects smoking rates across the globe—smokers in lower income households are less likely to have access to these smoke-free alternatives. As representatives from health ministries across the globe are shortly set to gather for an international meeting on tobacco control, we hope that other governments and regulators recognize the additional actions that the U.K. government is taking to offer better alternatives to adults who would otherwise continue to smoke cigarettes.”

PMI agrees that smoke-free products—under clear regulations and thorough scientific assessments—while not risk-free, are less harmful than continued smoking and can significantly benefit the public health. Regulators can decisively accelerate the achievement of a future without cigarettes through risk-proportionate regulations for all nicotine-containing consumer products. A growing number of countries—including the US, New Zealand, Italy, Portugal, Greece and Bulgaria—have recognized this approach and implemented differentiated regulation for noncombustible alternatives. Many others are debating changes to their regulation. All men and women who would otherwise continue to smoke cigarettes, regardless of their income level and where they live, should have access to and accurate information about products that are a better alternative.

Whilst PMI does not believe that smoke-free products should be sold exclusively in pharmacies, because access through a wide range of regulated channels is critical to adoption, the company welcomes a simplified, medicinal route implemented in addition to other comprehensive regulatory and supply measures to accelerate adoption of smoke-free products. The company further believes that a smoke-free future is attainable, and that this future can be achieved more rapidly if all stakeholders work collaboratively. Together with governments and civil society, the opportunity to rid the world of combustible cigarettes can be maximized through a consensus that smoke-free alternatives, when subject to proper government oversight and regulation, are part of a sound tobacco harm reduction policy.

Notes to Editors:

Sources

  1. E-cigarettes could be prescribed on the NHS in world first - GOV.UK (www.gov.uk)
  2. Adult smoking habits in the UK - Office for National Statistics (ons.gov.uk)
  3. Smoking among adults | Health at a Glance: Europe 2020 : State of Health in the EU Cycle | OECD iLibrary (oecd-ilibrary.org)

Smoke-free products in the U.K.

  • The U.K. has a well-established consumer market for smoke-free products, having developed over the past decade.
  • The U.K. e-cigarette market is diverse, with estimates suggesting there are around 3.6 million vapers in Great Britain. (Use-of-e-cigarettes-vapes-among-adults-in-Great-Britain-2021.pdf (ash.org.uk))
  • U.K. authorities take an evidence-based approach to e-cigarettes to date, with Public Health England concluding that e-cigarettes are less harmful than smoking ((2015) E-cigarettes: an evidence update - GOV.UK (www.gov.uk)).
  • Over the last 5 years, other categories of smoke-free alternatives have also grown in the U.K., such as the Heated Tobacco category where there are now two competitor products on the market, includingPMI’s IQOS which has been the U.K.’s number one smoke-free product since June 2020 (Nielsen data).

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders, and other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, versions of PMI’s IQOS Platform 1 device and consumables have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn products, nicotine-containing vapor products, and oral nicotine products. As of September 30, 2021, PMI’s smoke-free products are available for sale in 70 markets in key cities or nationwide, and PMI estimates that approximately 14.9 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Philip Morris International
Trinh Nguyen
Philip Morris International
T. +1 (202) 777 4307
E. Trinh.Nguyen@pmi.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University3.12.2021 16:00:00 CET | Press release

NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time. NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rar

Healthcare + Expo Taiwan to Build an Ecosystem of Digital Transformation in Healthcare3.12.2021 15:15:00 CET | Press release

One of the largest trade fairs in the APAC region- the Healthcare+ Expo Taiwan- takes place on 2 to 5 December in Taipei. The Expo displays Taiwan’s strength in AI, Cloud-based Applications, Flat Panels, IoT and Technologies that make up Metaverse, reflecting the trend on digital transformation in healthcare driven by the global pandemic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211203005002/en/ Expand Businesses into growing markets in the APAC region, with Healthcare+ B2B. Join medical institutes and companies in the fields of pharmaceuticals, biotechnology, health/ information technology, electronics and manufacturing to promote products, build partnerships and seize supply-demand opportunities. (Graphic: Business Wire) The Expo has an all-star lineup of corporates, including Acer, Asus, AUO, Delta Electronics, Innolux, Quanta and Wistron, demonstrate their technologies and solutions tailored to digital transformati

Eurofins Technologies Launches a New Multiplex RT-PCR Assay for Combined SARS-CoV-2 Screening and Rapid Detection of the Omicron (B.1.1.529) Variant of Concern3.12.2021 14:05:00 CET | Press release

Eurofins Technologies (Paris:ERF) announces the launch of the multiplex RT-PCR assay GSD NovaType Detect + Select K417N SARS-CoV-2. Within just one week since the first reports on the Omicron variant of concern, this kit has been developed as a quick response to identify its presence. The assay is designed for the simultaneous qualitative detection of SARS-CoV-2 genomic RNA and identification of the spike (S) mutation K417N in one reaction. The results of this RT-PCR assay can be obtained within 1 hour, which makes it a fast and cost-effective solution to identifying the presence of the Omicron variant before samples are confirmed by whole genome sequencing. Eurofins Technologies is constantly working to adapt its product offering to meet the challenges of the ongoing COVID-19 pandemic.. For more information, please visit Eurofins Technologies website. About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection m

How Can Chinese Cities Increase Their Global Communications Impact? Joint Report and Index from CCG and Xinhuanet Sizes up Strategies and Offers Valuable Suggestions3.12.2021 13:53:00 CET | Press release

The Center for China and Globalization (CCG) and Xinhuanet, China’s leading online news portal, recently released a joint report evaluating the global communications impact of Chinese cities, analyzing the problems with their communication strategies, and offering suggestions on improving their ability to “go global”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211203005279/en/ Report on the Chinese Cities Global Communications Impact Index (CCGCII) & Ranking of Chinese Cities by Global Communications Impact (Graphic: Business Wire) The study covered the top 100 cities in China as ranked by GDP in 2019, including Shanghai, Beijing, Shenzhen, Guangzhou, Chongqing, Chengdu, Wuhan, Tianjin, Dalian, and Xiamen . Based on big data from the Xinhua RIS data bank, which has collated over 10 million items of public information from overseas mainstream media and international social media platforms, the Chinese Cities Global Commun

Valuence Japan Nanboya, BRAND CONCIER Recognized as No.1 in Five Categories in Japan, Including for Overall Purchase Volume, for Luxury Brand Goods and Other Items!3.12.2021 10:55:00 CET | Press release

Valuence Japan Inc. (Tokyo; Susumu Muguruma, representative director), a member of the Valuence Group (TOKYO:9270), which operates 135 offices in Japan and 23 other countries(*1) specializing in the purchase of watches, bags, jewelry, precious metals, antiques, and art objects has announced the results of a survey on the purchase volume of brand goods conducted by ESP Research Institute, Inc. According to the survey, the company’s Nanboya and BRAND CONCIER brands placed in the top position in Japan in terms of overall annual purchase volume of luxury brand goods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211203005167/en/ Valuence Japan Nanboya, BRAND CONCIER Recognized as No.1 in Five Categories in Japan, Including for Overall Purchase Volume, for Luxury Brand Goods and Other Items! Also Recognized as No.1 in Japan for Purchase Volume of Rolex and Other Watches, Jewelry, Apparel, and Accessories (Graphic: Business Wire)

Moody’s Acquires PassFort and Agrees to Acquire kompany, Expanding KYC and Compliance Capabilities3.12.2021 10:00:00 CET | Press release

Moody’s Corporation (NYSE:MCO) announced today that it has acquired PassFort Limited and entered into an agreement to acquire 360kompany AG (kompany), two European providers of onboarding and Know Your Customer (KYC) technology solutions. The acquisitions complement Moody’s technology, data, and analytical capabilities, and enhance its industry-leading customer solutions for KYC, anti-money laundering, compliance, and counterparty risk. “Our customers rely on our data and analytical tools to make decisions about who they do business with,” said Keith Berry, General Manager of Moody’s KYC business unit. “PassFort and kompany are innovators in the compliance and regulatory space, and their technologies will upgrade and accelerate our customers’ onboarding and monitoring processes.” PassFort is a U.K. SaaS-based workflow platform for identity verification, customer onboarding, and risk analysis. Its software delivers data from over 25 third-party providers and automates the collection, ve

DEXLEVO's Liquid Polymer Filler Raises KRW 26 Billion in Pre-IPO Funding3.12.2021 08:41:00 CET | Press release

DEXLEVO has completed its pre-IPO funding of KRW 26 billion. It thus increased its valuation by six times compared to the Series B funding in 2018 thanks to its commercialization performance such as obtaining the European Union’s CE certification on the liquid polymer filler (product name: GOURI) in May of this year. The company plans to build a new cGMP-grade (current Good Manufacturing Practice) production facility in Songdo with the proceeds raised this time and start marketing its flagship product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202006086/en/ DEXLEVO's GOURI, the world's 1st Fully Liquid type PCL Injectable. (Graphic: Business Wire) According to industry sources on November 25, DEXLEVO has completed a total of KRW 26 billion in pre-IPO funding from existing investors such as Magna Investment, Smilegate Investment, Hyundai Venture Investment Corp., and Shinhan Capital. Magna Investment and Smilegate Inv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom